Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1967 Mar;20(2):152–157. doi: 10.1136/jcp.20.2.152

Hypofibrinogenaemia in metastatic carcinoma of the prostate: suppression of systemic fibrinolysis by heparin

P W Straub 1, G Riedler 1, P G Frick 1
PMCID: PMC473445  PMID: 5602506

Abstract

In a patient with generalized prostatic carcinoma and hypofibrinogenaemia heparin infusion on four occasions abolished systemic fibrinolysis as determined by euglobulin clot lysis time, bovine fibrin plate assay, thromboelastography, and immunoelectrophoretic demonstration of fibrinogen split products.

The pathogenesis of hypofibrinogenaemia in cases of prostatic carcinoma and the possibility of a direct heparin effect on fibrinolysis are discussed. Despite the lack of histological evidence for intravascular coagulation, the findings are considered additional evidence for the view that fibrinolysis in this syndrome may be secondary to intravascular coagulation.

Full text

PDF
152

Images in this article

155Image
on p.155

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ABOULKER P., SOULIER J. P., LARRIEU M. J., WARTELLE O. Syndrome hémorragique avec fibrinolyse associé au cancer de la prostate. Presse Med. 1955 Mar 9;63(18):353–354. [PubMed] [Google Scholar]
  2. ALKJAERSIG N., FLETCHER A. P., SHERRY S. The mechanism of clot dissolution by plasmin. J Clin Invest. 1959 Jul;38(7):1086–1095. doi: 10.1172/JCI103885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. ANDERSSON L., NILSSON I. M. Effect of 6-amino-n-caproic acid (6-ACA) on fibrinolysis and bleeding conditions in prostatic disease. Acta Chir Scand. 1961 May;121:291–298. [PubMed] [Google Scholar]
  4. ASTRUP T., ALKJAERSIG N. Classification of proteolytic enzymes by means of their inhibitors. Nature. 1952 Feb 23;169(4295):314–316. doi: 10.1038/169314a0. [DOI] [PubMed] [Google Scholar]
  5. ASTRUP T., CROOKSTON J., MACINTYRE A. Proteolytic enzymes in blood. Acta Physiol Scand. 1950 Nov;21(2-3):238–249. doi: 10.1111/j.1748-1716.1950.tb00732.x. [DOI] [PubMed] [Google Scholar]
  6. BERGEN S., Jr, SCHILLING F. J. Circulating fibrinolysin in a case of prostatic carcinoma with bony metastases. Ann Intern Med. 1958 Feb;48(2):389–398. doi: 10.7326/0003-4819-48-2-389. [DOI] [PubMed] [Google Scholar]
  7. BOROS M., TARNOKY K., VERECZKEY C., RAK K. [Cryofibrinogenemia and pathologically increased fibrinolysis a patient with prostate cancer]. Z Klin Med. 1962;157:68–76. [PubMed] [Google Scholar]
  8. BREDT J. [Hyperfibrinolysis in prostatic carcinoma]. Blut. 1962 Mar;8:22–28. doi: 10.1007/BF01570368. [DOI] [PubMed] [Google Scholar]
  9. CLAUSS A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 1957 Apr;17(4):237–246. doi: 10.1159/000205234. [DOI] [PubMed] [Google Scholar]
  10. COSGRIFF S. W., LEIFER E. Factor 5 deficiency in hemorrhagic diathesis (parahemophilia). J Am Med Assoc. 1952 Feb 9;148(6):462–463. doi: 10.1001/jama.1952.62930060003012b. [DOI] [PubMed] [Google Scholar]
  11. COTTIER P., LEUPOLD R., SCHEITLIN W. Die hämorrhagische Diathese bei Prostatakarzinom und ihre Behandlung. Schweiz Med Wochenschr. 1955 Aug 13;85(33):781–786. [PubMed] [Google Scholar]
  12. CRANE J. J., WARE A. G., HAMILTON J. Spontaneous afibrinogenemia in cancer of prostate; report of two cases. J Urol. 1955 Feb;73(2):379–383. doi: 10.1016/S0022-5347(17)67411-1. [DOI] [PubMed] [Google Scholar]
  13. DANIEL O., SWAN H. T., WOOD K. F. Dangerous bleeding associated with carcinoma of prostate. Br Med J. 1957 Mar 2;1(5017):495–498. doi: 10.1136/bmj.1.5017.495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. FRICK P. G. Acute hemorrhagic syndrome with hypofibrinogenemia in metastatic cancer. Acta Haematol. 1956 Jul;16(1):11–29. doi: 10.1159/000205113. [DOI] [PubMed] [Google Scholar]
  15. GIACOMAZZI G. L'influenza dell'eparina sulla fibrinolisi. Policlinico Med. 1955 Jul-Aug;62(4):226–239. [PubMed] [Google Scholar]
  16. GREIG H. B. Inhibition of fibrinolysis by alimentary lipaemia. Lancet. 1956 Jul 7;271(6932):16–18. doi: 10.1016/s0140-6736(56)91388-5. [DOI] [PubMed] [Google Scholar]
  17. HARTERT H. Die Thrombelastographie, eine Methode zur physikalischen Analyse des Blutgerinnungsvorganges. Z Gesamte Exp Med. 1951;117(2):189–203. [PubMed] [Google Scholar]
  18. HOLEMANS R., ADAMIS D., HORACE J. F. INTERACTION OF HEPARIN WITH FIBRINOLYSIS. Thromb Diath Haemorrh. 1963 Jul 15;143:446–458. [PubMed] [Google Scholar]
  19. HUME R. Fibrinolysis in myocardial infarction. Br Heart J. 1958 Jan;20(1):15–20. doi: 10.1136/hrt.20.1.15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. KARHAUSEN L., TAGNON H. Le syndrome de fibrinolyse prostatique; nature de l'activité protéolytique de la prostate. Acta Clin Belg. 1955 Nov-Dec;10(6):471–476. doi: 10.1080/17843286.1955.11717370. [DOI] [PubMed] [Google Scholar]
  21. KONTTINEN Y. The effect of heparin on the fibrinolytic activity of streptokinase-activated human plasma. Scand J Clin Lab Invest. 1962;14:15–18. [PubMed] [Google Scholar]
  22. LACKNER H., MERSKEY C. Variation in fibrinolytic activity after acute myocardial infarction and after the administration of oral anticoagulant drugs and intravenous heparin. Br J Haematol. 1960 Oct;6:402–413. doi: 10.1111/j.1365-2141.1960.tb06259.x. [DOI] [PubMed] [Google Scholar]
  23. LEWIS J. H., KERBER C. W., WILSON J. H. EFFECTS OF FIBRINOLYTIC AGENTS AND HEPARIN ON INTRAVASCULAR CLOT LYSIS. Am J Physiol. 1964 Nov;207:1044–1048. doi: 10.1152/ajplegacy.1964.207.5.1044. [DOI] [PubMed] [Google Scholar]
  24. MERSKEY C., JOHNSON A. J., PERT J. H., WOHL H. PATHOGENESIS OF FIBRINOLYSIS IN DEFIBRINATION SYNDROME: EFFECT OF HEPARIN ADMINISTRATION. Blood. 1964 Dec;24:701–715. [PubMed] [Google Scholar]
  25. MILLER J. M., MEISEL H. J., JACKSON D. A., COLLIER C. S. Fibrinolysis in a patient with carcinoma of the prostate. J Urol. 1959 May;81(5):672–675. doi: 10.1016/S0022-5347(17)66090-7. [DOI] [PubMed] [Google Scholar]
  26. NAEYE R. L. Thrombotic state after a hemorrhagic diathesis, a possible complication of therapy with epsilon-aminocapproic acid. Blood. 1962 Jun;19:694–701. [PubMed] [Google Scholar]
  27. PALY S. N., KLINE D. L. The spontaneous proteolytic activity of dog blood. Yale J Biol Med. 1954 Jun;26(6):486–490. [PMC free article] [PubMed] [Google Scholar]
  28. PHILLIPS L. L., SKRODELIS V., FUREY C. A. The fibrinolytic enzyme system in prostatic cancer. Cancer. 1959 Jul-Aug;12(4):721–730. doi: 10.1002/1097-0142(195907/08)12:4<721::aid-cncr2820120415>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  29. PROCTOR N. S., KAUFMANN J. C. Subacute inclusion encephalitis in South Africa. Lancet. 1963 Mar 9;1(7280):555–556. doi: 10.1016/s0140-6736(63)91359-x. [DOI] [PubMed] [Google Scholar]
  30. PROUT G. R., SIEGEL M., CLIFFTON E. E., WHITMORE W. F., Jr Hemorrhagic diathesis in patients with carcinoma of prostate. J Am Med Assoc. 1956 Mar 10;160(10):840–846. doi: 10.1001/jama.1956.02960450022006. [DOI] [PubMed] [Google Scholar]
  31. RAPAPORT S. I., CHAPMAN C. G. Coexistent hypercoagulability and acute hypofibrinogenemia in a patient with prostatic carcinoma. Am J Med. 1959 Jul;27(1):144–153. doi: 10.1016/0002-9343(59)90069-5. [DOI] [PubMed] [Google Scholar]
  32. SANDRITTER W., BERGERHOF H. D., KROKER R. Morphologische Untersuchungen zur Wirkung des Heparins auf experimentelle Abscheidungsthromben. Frankf Z Pathol. 1954;65(3):342–349. [PubMed] [Google Scholar]
  33. SCHEIDEGGER J. J. Une micro-méthode de l'immuno-electrophorèse. Int Arch Allergy Appl Immunol. 1955;7(2):103–110. [PubMed] [Google Scholar]
  34. SCHMIDHAUSER-KOPPM, EICHENBERGER E. Uber den Einfluss von Thrombin und Heparin auf die Fibrinolyse. Experientia. 1952 Sep 15;8(9):354–355. doi: 10.1007/BF02174416. [DOI] [PubMed] [Google Scholar]
  35. SCHULTZE H. E., SCHWICK G. Uber den Mechanismus der Thrombinbildung im isolierten System. Hoppe Seylers Z Physiol Chem. 1951;289(1):26–43. [PubMed] [Google Scholar]
  36. SEALE R. A., JAMPOLIS R. W., BARGEN J. A. Clotting defect in the presence of metastatic carcinoma of prostate; a case report. Surg Clin North Am. 1951 Aug;31(4):1111–1119. doi: 10.1016/s0039-6109(16)33392-8. [DOI] [PubMed] [Google Scholar]
  37. SIGSTAD H., LAMVIK J. Haemorrhagic diathesis, fibrinolysis and fibrinogenopenia in prostatic cancer. Report of a case. Acta Med Scand. 1963 Feb;173:215–222. doi: 10.1111/j.0954-6820.1963.tb16525.x. [DOI] [PubMed] [Google Scholar]
  38. STEFAN H., CHROBAK L., NERAD V., GROH J. [Hypofibrinogenenia and fibrinolysis as a cause of hemorrhage in prostate carcinoma]. Z Urol. 1959 Dec;52:735–743. [PubMed] [Google Scholar]
  39. STOCKER H., MAIER C. CHRONISCHE FIBRINOLYSE BEI PROSTATAKARZINOM. Schweiz Med Wochenschr. 1964 Sep 26;94:1373–1374. [PubMed] [Google Scholar]
  40. TAGNON H. J., SCHULMAN P., WHITMORE W. F., LEONE L. A. Prostatic fibrinolysin; study of a case illustrating role in hemorrhagic diathesis of cancer of the prostate. Am J Med. 1953 Dec;15(6):875–884. doi: 10.1016/0002-9343(53)90178-8. [DOI] [PubMed] [Google Scholar]
  41. TAGNON H. J., WHITMORE W. F., Jr, SHULMAN N. R. Fibrinolysis in metastatic cancer of the prostate. Cancer. 1952 Jan;5(1):9–12. doi: 10.1002/1097-0142(195201)5:1<9::aid-cncr2820050104>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  42. VON KAULLA K. N., McDONALD T. S. The effect of heparin on components of the human fibrinolytic system. Blood. 1958 Aug;13(8):811–821. [PubMed] [Google Scholar]
  43. ZEH E., OTT H. Klinische Gesichtspunkte zur Entstehung der erworbenen Afibrinogenämie und Fibrinogenopenie mit hämorrhagischer Diathese; Beschreibung eines neuen Falles. Acta Haematol. 1954 Aug;12(2):106–116. doi: 10.1159/000204606. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES